GSK supports HIV association CASAPC to launch online HCP education project

Today, the Chinese Association of STD and AIDS Prevention and Control (CASAPC; “the Association”) and GSK China launched the “Online Digital Physician Education Project” for AIDS prevention and control.

Today, the Chinese Association of STD and AIDS Prevention and Control (CASAPC; “the Association”) and GSK China launched the “Online Digital Physician Education Project” for AIDS prevention and control. Representatives from both sides including Xiaoqiu Qi, President of the Association, Yang Hao, Vice President, Xinlun Wang, Secretary-General, Siyuan Chen, VP, Head of Specialty Care Business Unit, GSK China, as well as HIV/AIDS prevention and control experts attended the event in Beijing. 

In a recent National Health Commission briefing, it pointed out that the allocation of quality healthcare resources to under-resourced regions by leveraging “Internet+” technologies will help address regional disparities in resources. Echoing this critical national initiative, the project aims to keep China’s HIV/AIDS prevention and control experts and scholars up to date with the latest in scientific and medical advancements in the field, and enhance the country’s ability to diagnose and treat HIV/AIDS.

As part of the project, the HIV/AIDS Knowledge Academy, an educational WeChat platform, has been launched. Through this online platform, physicians working in the diagnosis and treatment of HIV/AIDS, especially those in remote areas with a high incidence of HIV infection, will be able to keep up with the latest advances in innovative and effective HIV/AIDS prevention and treatment. This, in turn, is expected to equip them with the knowledge needed to boost their diagnostic and treatment capability. Within three years, this platform is set to cover close to 6,000 physicians and public health scholars nationwide. 

Xiaoqiu Qi, President of the Association, said, “The Association is a voluntary, professional national non-profit NGO, where individuals, companies, institutions and social organisations work together to prevent and control HIV/AIDS. As a key NGO player in HIV/AIDS prevention and control in China, we build a bridge between the government and the NGO sectors. Through the HIV/AIDS Knowledge Academy, we hope to enhance the capability of HIV/AIDS prevention and control professionals at the primary care level on one hand, and on the other, fully implement China’s ‘Internet + Healthcare’ strategy and support the government in its HIV/AIDS prevention and control plan.”

Siyuan Chen, VP, Head of Specialty Care Business Unit at GSK China, said, “GSK has always supported the Chinese government’s key healthcare reform initiatives. One important commitment we have made to China is to improve primary care physicians’ access to innovative solutions to disease prevention and control. Therefore, we will work closely with the Association to bolster the capability of physicians in diagnosing and treating HIV/AIDS through the online digital platform, so that the people living with HIV in China can receive better treatment.”

Professor Fujie Zhang spoke on behalf of experts in AIDS prevention and control. He said, “We are ready to share our professional expertise in diagnosis and treatment with physicians nationwide, especially those working in primary care and remote areas, through this platform. We hope to help them enhance their capability in HIV/AIDS prevention and control and to contribute to the government’s HIV/AIDS prevention and control efforts.”

Xiaoqiu Qi, President of the Association, and Siyuan Chen, VP, Head of Specialty Care Business Unit at GSK China, signed the MOU for collaboration on the Online Digital Physician Education Project for AIDS prevention and control. The signing was followed by extensive discussions and appraisal of the project’s online modules and contents by the attendees from the Association and GSK China, and experts attending the ceremony.


GSK in China with China for China

GSK is committed to supporting the healthcare reform of the Chinese government and to ensuring that Chinese patients can access our innovative treatments targeting their specific needs. As part of our strategy to be "in China, with China, for China", we have achieved the following milestones in recent years:


  • GSK China partners with JD to drive “Internet + Healthcare” to improve patient experience and access to healthcare in May 2018.
  • Anoro Ellipta, a new once-daily dual bronchodilators treatment for COPD, was approved in March 2018.
  • Our innovative antiretroviral Single Tablet Regimen (STR) Triumeq was officially launched in January 2018.
  • Supported the launch of “New Respiration and Frequent Care” online management platform for asthma patients in December 2017.
  • Supported the launch of the UK-China Health and Economy Partnership in November 2017.
  • Supported the launch of "Happy Breath" COPD Tiered Diagnosis and Treatment Project across China in November 2017.
  • Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in August 2017.
  • Innovative antiretroviral Single Tablet Regimen (STR) Triumeq received approval in China in August 2017.
  • Cervarix, the first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Seroxat CR and Tykerb were included into the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Viread, Arixtra, Requip and Mivacron were included in the “2017 National Reimbursement Drug List” in March 2017.


GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


Media enquiries:

Susan Song  (GSK China)